MedTech Europe in the headlines in June 2026
Posted on 02.07.2026
The recent media coverage showcased key structural challenges shaping Europe’s medtech landscape, from regulation to investment to value creation.
Industry urges dedicated support for Europe’s €13B IVD sector
Position paper on IVDR revision welcomes many of the EU’s proposed changes, but requests tweaks to orphan diagnostics, risk classifications and health institution tests. MedTech Insight noted that the new document follows the association’s May publication of an overall position paper on the European Commission’s proposed revisions to both the Medical Device Regulation and IVDR. The publication of the IVDR position paper was also covered by the Regulatory Affairs Professionals Society (RAPS) and Medical Buyer.
EU Notified Bodies cut staff, cite slowdown in technical doc submissions
“A more proportionate, risk-based, and predictable system will better support timely patient access and strengthen Europe’s attractiveness for innovation,” Petra Zoellner, Director of regulatory affairs (IVDR and MDR) for MedTech Europe argues in MedTech Strategist. She highlighted the urgent need for a simplified regulatory framework.
The 2026 MedTech Forum: The medtech investment gap
Coverage from the MedTech Europe’s flagship event continued well beyond its conclusion. MedTech Insight reported from the MedTech Forum 2026 panel discussion on Europe’s attractiveness that Europe holds 27% of the global medtech market and some of its most active innovation clusters, but captures barely a fifth of global venture capital. That gap is not a funding problem. It is a failure to convert scientific strength into scalable businesses.
Healthcare providers look beyond price to deliver better value
In a paper published last month, the King’s Fund argued that value-based procurement could “transform NHS innovation adoption by enabling fair risk sharing with suppliers.” Such an approach has already been adopted in Europe, where MedTech Europe has teamed up with the Boston Consulting Group to produce a framework based around a simple equation of value equalling patient outcomes divided by the total cost of care rather than just the initial price of a product, Forbes reported.